H&E staining demonstrated that no noticeable tissue damage and inflammatory lesion were caused in the vital organs of the mice and rabbits (Fig. ). To further investigate the potential toxicology of DIPT-ICF NPs, healthy Balb/c nude mice and rabbits intravenously administrated with DIPT-ICF NPs (0.5 mg/mL based on DIPT-ICF) as well as untreated healthy mice and rabbits were received serum biochemistry assay and complete blood count after 14 days post injection. The liver function indicators, including alanine aminotransferase (ALT), aspartic acid transaminase (AST), blood urea nitrogen (BUN), and Serum creatinine (Scr) were all measured to be normal (Fig. ), revealing that no obvious hepatic and renal disorders for DIPT-ICF NPs-treated mice and rabbits. Besides, the assay of the blood panel, including white blood cells (WBC), hemoglobin (Hgb), red blood cells (RBC), as well as platelets (PLT), indicates that there are not statistical differences in these indicators between DIPT-ICF NPs and untreated groups (Fig. ). These results indicated that DIPT-ICF NPs was a highly biocompatible and biosafety contrast agent without noticeable side effects on living mice and rabbits, which benefits the translation of AIE NPs-assisted angiography and bioimaging for clinical applications.